Respiratory Pathogens

  1. Home
  2. /
  3. Service
  4. /
  5. Respiratory Pathogens

Respiratory Pathogens

  1. Home
  2. /
  3. Service
  4. /
  5. Respiratory Pathogens

Our Testing Services

Pharmacogenomics (PGx)

Pharmacogenomics studies a person’s DNA to test how it responds to different drugs. Researchers have found that different people have different reactions to the same drug. We test genetic variants for the best response to over 100 drugs.

Wound Pathogens

We can help you heal better with our qPCR-based test which detects the pathogens in the affected area. The results help with better wound management and prevent the spread of infection.

Blood Chemistry

An annual blood test is advised as part of an annual physical check-up to assess the health of your kidneys, liver, thyroid or heart.

Urine Drug Testing

We offer Specimen Validity Testing, Screening Assays and Liquid Chromatography-Tandem Mass Spectrometry.

Respiratory Pathogens

Devansh Lab Werk’s qPCR based RPP helps identify common viruses and mixed infections which will help your physician arrive at the correct diagnosis for you.

Urinary Tract Infection (UTI)

A UTI is usually caused by bacteria. While women are more likely to get a UTI, men are also at risk. It is important to identify the symptoms and get yourself tested before the condition becomes worse. Symptoms include increased frequency in urination, pelvic pain, cloudy urine etc.

Respiratory Pathogen Panel (RPP)

Upper respiratory tract infections (URTIs) are illnesses caused by infections in the upper respiratory tract including nose, sinuses, pharynx, or larynx. These cause throat, tonsillitis,sinusitis, otitis media, and the common cold, etc. There are two types of upper respiratory tract infections i.e. viral and bacterial. Improved diagnostic tests are being developed to identify and control URTIs.

Efforts to prevent and treat URTIs have led to the development of highly-multiplexed molecular respiratory pathogen panels (RPPs). These panels test the viral and bacterial agents of the upper respiratory tract infections. Devansh Lab also has a comprehensive qPCR-based RPP which screens 20 targets in a single test for the URTIs. This single test can help identify common viruses as well as mixed infections. Quick and accurate results allow healthcare providers to treat upper respiratory tract infections and contain them.

RPP Panel

  • Adenovirus
  • Bordetella pertussis
  • Human Bocavirus
  • Bordetella bronchiseptica/ parapertussis/ pertussis
  • Chlamydophila pneumoniae
  • Human Coronavirus 229E
  • Human Coronavirus HKU1
  • Human Coronavirus NL63
  • Human Coronavirus OC43
  • Human Enterovirus D68
  • Human Enterovirus (pan assay)
  • Haemophilus influenzae
  • Human Respiratory Syncytial Virus A (RSVB)
  • Human Respiratory Syncytial Virus B (RSVB)
  • Streptococcus pneumoniae
  • Human Rhinovirus
  • Human herpesvirus 3 (HHV3 – Varicella zoster Virus)
  • Human herpesvirus 4 (HHV4 – Epstein-Barr Virus)
  • Human herpesvirus 5 (HHV5 – Cytomegalovirus)
  • Human herpesvirus 6 (HHV6)
  • Human Metapneumovirus (hMPV)
  • Influenza A/H1-2009
  • Influenza A/H3
  • Influenza A
  • Influenza B
  • Klebsiella pneumoniae
  • Legionella pneumophila
  • Mycoplasma pneumoniae
  • Human Parainfluenza virus 1
  • Human Parainfluenza virus 2
  • Human Parainfluenza virus 3
  • Human Parainfluenza virus 4

Covid-19

  • SAARS COV-2

FAQ's

A respiratory pathogen panel (RPP) is a highly advanced molecular diagnostic test designed to detect viral and bacterial pathogens responsible for upper respiratory tract infections (URTIs). It identifies multiple pathogens, including influenza viruses, coronaviruses, and bacterial strains, in a single test using cutting-edge multiplex technology. 

RPP testing provides rapid and accurate detection of pathogens causing URTIs, enabling healthcare providers to: 

→  Identify infection-causing agents early 

Implement appropriate treatments without delay 

→  Reduce antibiotic misuse by distinguishing bacterial from viral infections.

→  Help prevent the spread of infectious diseases 

The Devansh Lab Werks RPP detects over 20 viral and bacterial pathogens in a single test, including: 

→  Influenza A and B 

→  Human coronaviruses (229E, HKU1, NL63, OC43) 

→  Human rhinovirus 

→  Streptococcus pneumoniae 

→  Bordetella pertussis 

→  Human herpesviruses and many others 

Devansh Lab Werks utilizes quantitative polymerase chain reaction (qPCR) technology, a highly sensitive molecular technique that amplifies and detects DNA/RNA of respiratory pathogens. This ensures accurate and reliable results, aiding in precise diagnosis and effective treatment planning. 

RPP testing offers several clinical advantages, such as: 

→  Simultaneous detection of viral and bacterial infections 

→  Faster results compared to traditional culture-based methods 

→  Identification of co-infections for tailored treatment 

→  Improved clinical decision-making and infection management 

Yes, Devansh Lab Werks RPP distinguishes between viral and bacterial infections by detecting the genetic material of specific pathogens. This helps healthcare providers determine whether antibiotics are necessary or if antiviral or symptomatic treatments should be recommended instead. 

The Devansh Lab Werks qPCR-based RPP delivers fast and highly accurate results, enabling healthcare professionals to make timely and informed clinical decisions. Rapid diagnosis ensures quicker initiation of targeted treatment, improving patient care. 

The high-throughput multiplex RPP offered by Devansh Lab Werks effectively detects co-infections involving multiple pathogens. This allows for comprehensive disease profiling, helping physicians design personalized treatment strategies for improved patient outcomes. 

Yes, RPP testing is crucial during flu and COVID-19 outbreaks as it can simultaneously detect influenza, SARS-CoV-2, and other respiratory viruses. This enables: 

→  Early and accurate diagnosis of overlapping symptoms 

→  Faster outbreak management and containment 

→  Targeted medical interventions to improve patient prognosis 

Individuals experiencing persistent or severe respiratory symptoms, such as fever, cough, shortness of breath, or fatigue, should consider RPP testing. It is especially beneficial for: 

→  Immunocompromised patients at higher risk of complications 

→  Hospitalized patients with unexplained respiratory symptoms 

→  People exposed to respiratory illness outbreaks